Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
Clinical trial NCT06749860 · RECRUITING
Trial details
- NCT number
- NCT06749860
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-02
- Primary completion
- 2026-06-06
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.